Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of AK104 plus concurrent chemoradiotherapy in locally advanced cervical cancer
CTR20220112Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Jun 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in Cervical Cancer (CC), sponsored by Akeso, Inc.. Started Jun 2022; status: active.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20220112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220112.